In Brief: Renova
This article was originally published in The Tan Sheet
Executive Summary
Renova: Johnson & Johnson's Ortho subsidiary to launch Rx skin treatment in February after Dec. 29 approval by FDA. Renova (tretinoin emollient cream .05%) is indicated as an "adjunctive agent for use in the mitigation of fine wrinkles, mottled hyperpigmentation and tactile roughness of facial skin." In clinical trials, most of the skin improvement occurred during the first 24 weeks. "The safety and effectiveness of using Renova daily for greater than 48 weeks have not been established," labeling notes. Renova is contraindicated in pregnant women or those at high risk for pregnancy due to a lack of safety data in those subjects...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning